Navigation Links
China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2013
Date:11/5/2013

BEIJING, Nov. 5, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the third quarter of 2013.

Third Quarter 2013 Financial Highlights

  • Total sales in the third quarter of 2013 were $53.2 million, compared to $53.1 million in the same quarter of 2012.
  • Gross profit decreased slightly to $36.0 million from $36.2 million in the same quarter of 2012. Gross margin was 67.7% in the third quarter of 2013, compared to 68.1% in the third quarter of 2012.
  • Income from operations increased by 13.4% to $23.2 million from $20.4 million in the same quarter of 2012. Operating margin increased to 43.6% in the third quarter of 2013 from 38.4% in the same quarter of 2012.
  • Net income attributable to the Company increased by 7.9% to $14.7 million from $13.6 million in the same quarter of 2012. Fully diluted net income per share was $0.53 in the third quarter of 2013 as compared to $0.50 in the same quarter of 2012.
  • Non-GAAP adjusted net income attributable to the Company was $15.5 million, representing a 5.8% increase from $14.7 million in the same quarter of 2012. Non-GAAP adjusted net income per share was $0.56, compared to $0.54 in the same quarter of 2012.
  • Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, "We are pleased with our solid financial performance and sound operational execution in the third quarter, particularly in comparison with the third quarter in the prior year, which was also a strong quarter. Our Shandong facility experienced a double-digit sales increase in the third quarter and, as anticipated, our Guizhou facility suspended production since June 1, 2013. The financial impact associated with our Guizhou facility remains in-line with our internal forecast and
    '/>"/>

    SOURCE China Biologic Products, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Governor-General of Australia Ms. Bryce Visits Sichuan University and Investigates Australia Cochlear Cochlea Project in West China Hospital, Sichuan University
    2. The Medical Device Market: China
    3. China Biologic Products to Report Third Quarter 2013 Financial Results
    4. MEDTEC China 2013: Close to 8,000 Industry Professionals Make Show an Outstanding Success
    5. What U.S. Doctors Know That Has Not Yet Reached China
    6. PharmaPoint: Alzheimers Disease - China Drug Forecast and Market Analysis to 2022
    7. Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China
    8. China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 25, 2013
    9. MEDTEC China 2013: Shaping Up to be The Most Successful Event Ever
    10. PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022
    11. Ventana receives approval from Chinas FDA for first fully automated IHC companion diagnostic identifying ALK protein expression in lung cancer patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
    (Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
    (Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
    Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
    ... , HELSINKI, Dec. 14 Cancer ... with the introduction of RapidArc® radiotherapy technology from Varian Medical ... radiotherapy clinic in the Nordic region. Clinicians at Docrates Clinic ... radiotherapy to treat patients with multiple brain metastases and cancers ...
    ... , WALTHAM, Mass., Dec. ... authority on medical technology market intelligence, increased use of safety ... be a key driver of the enteral feeding device markets ... and European Markets for Enteral Feeding Devices 2010 report ...
    Cached Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3
    (Date:9/1/2015)... ... September 01, 2015 , ... Specialty Technical Publishers ... International Audit Protocol Consortium (IAPC) EHS audit protocol for the European Union. Leading ... of their EHS regulatory obligations and rapidly collect, share, archive, and export audit ...
    (Date:8/31/2015)... NJ (PRWEB) , ... September 01, 2015 , ... ... spine to eliminate chronic back pain – once required a long, arduous recovery. ... shorter hospital stay, less pain, less blood loss and minimal muscle damage. These ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Dental clinicians ... University of Health Sciences to learn more about its integrated approach to diabetes ... Sciences and Institute of Cellular Medicine at Newcastle University, and Susan Bissett, National ...
    (Date:8/31/2015)... Sierra Madre, CA (PRWEB) , ... August 31, ... ... partnered wound center management, recently opened registration for the company’s second Introduction to ... will be held October 15-18, 2015 aboard the Queen Mary Hotel in Long ...
    (Date:8/31/2015)... ... August 31, 2015 , ... CareSource, a nonprofit Ohio-based ... In this capacity, Michael will provide strategic leadership for CareSource’s marketing, branding, corporate ... programs that have contributed to the company’s rapid growth. As the CareSource business ...
    Breaking Medicine News(10 mins):Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:CareSource Names Vice President, Marketing and Corporate Communications 2
    ... Nov. 9 NutraCea (OTC Bulletin Board:,NTRZ), a ... stabilized rice bran,(SRB), announced today that it will ... 14 after the market closes. Management will ... 5:30 PM EST,to review NutraCea,s 2007 third quarter ...
    ... The medical director of the,famed Los Angeles Jewish Home ... for increased understanding of an,illness that is the 11th ... older,and expected to grow even more widespread in coming ... Alzheimer,s disease;,and unless a cure or significant treatment is ...
    ... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... a novel, oral Syk kinase inhibitor, in patients,with ... showed that R788 (tamatinib fosdium) can improve,platelet counts ... attacks and,destroys its own blood platelets. Initiated ...
    ... announce their new Guideline on the Management of Nonmuscle ... are diagnosed with bladder cancer, which has been linked ... and exposure to hazardous chemicals. The AUA originally published ... is an update to that document. , The Guideline ...
    ... one in four men admitted to hospital with acute urinary retention ... today. , The risk of death in men after acute urinary ... broken hip. The problem is set to get worse as the ... the sudden inability to pass urine and is often a progression ...
    ... nation,s first Vioxx trial, hails settlement as ,the ... right thing ... Firm are,announcing a nationwide settlement agreement with pharmaceutical giant,Merck & Co. Inc. ... injury lawsuits in the U.S. over Vioxx, the company,s,controversial pain medication. ...
    Cached Medicine News:Health News:NutraCea to Host Third Quarter 2007 Financial Results Conference Call November 14 2Health News:Increased Understanding Called for During November National Alzheimer's Disease Awareness Month by Los Angeles Jewish Home's Medical Director 2Health News:Increased Understanding Called for During November National Alzheimer's Disease Awareness Month by Los Angeles Jewish Home's Medical Director 3Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 2Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 3Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 4Health News:AUA releases new guidelines on non-muscle invasive bladder cancer 2Health News:Study reveals high death toll after severe urinary complications in men over 45 2Health News:The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc. 2
    ... designed for PCR amplification and target ... systems. The NGEN product line includes ... associated with cystic fibrosis, thrombosis, and ... for the detection of sequences associated ...
    ... pregnancy testing, our new ICON 25 hCG ... you fast, accurate results, plus Beckman Coulter ... hCG offers CLIA waived simplicity for urine ... For the hospital, it's the perfect complement ...
    AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
    Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
    Medicine Products: